CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION

January 4, 2002 / Vol. 50 / Nos. 51 & 52

MMWR™
MORBIDITY AND MORTALITY
WEEKLY REPORT

Raccoon Roundworm Encephalitis — Chicago, Illinois, and Los Angeles, California, 2000

Baylisascaris procyonis (BP), a common roundworm found in the small intestine of raccoons, causes severe or fatal encephalitis (neural larva migrans [NLM]) in a variety of birds and mammals, including humans (*1–8*). BP also can cause human ocular and visceral larva migrans (*1,2,9*). Humans become infected with BP by ingesting soil or other materials (e.g., bark or wood chips) contaminated with raccoon feces containing BP eggs (*2*). Young children are at particular risk for infection as a result of behaviors such as pica and geophagia and placing potentially contaminated fingers and other objects (e.g., toys) into their mouths. This report describes two cases of BP encephalitis in residents of Chicago and Los Angeles and illustrates the importance of reducing exposure to raccoons and their feces in U.S. urban areas.

Chicago

During July 2000, a boy aged 2½ years with a history of iron deficiency anemia and pica was admitted to a Chicago hospital with a low-grade fever of 8 days duration and increasing lethargy, irritability, and ataxia during the 3 days preceding admission. A diagnosis of encephalitis was made based on the clinical presentation and laboratory findings on admission, including peripheral eosinophilia (28% of 21,000 white blood cells/mm^3), cerebrospinal fluid (CSF) eosinophilic pleocytosis (32% of 80 white blood cells/mm^3), and diffuse slow waves on an electroencephalogram. Less than 24 hours after admission, the patient lapsed into a coma with opisthotonus and decerebrate posturing; magnetic resonance imaging (MRI) revealed abnormalities in the deep white matter of both cerebellar hemispheres. Other possible causes of encephalitis (e.g., herpes simplex; arboviruses and enteroviruses; lymphocytic choriomeningitis; measles; and bacterial, fungal, and parasitic infections [e.g., toxocariasis and cysticercosis]) were excluded based on direct examination, culture, serology, and polymerase chain reaction (PCR) testing of blood and CSF. Antibodies to BP were detected in CSF and serum specimens by indirect immunofluorescence assay (IFA) (*6,8*) with titers increasing several fold and reaching high levels (1:1,024 in CSF and 1:4,096 in serum specimens) during the 4 weeks following admission. The child was treated with albendazole and corticosteroids, but his condition did not improve. After 4 weeks of hospitalization, he was transferred to a rehabilitation center where he stayed for several months. He then was sent home where he remains profoundly neurologically disabled and in need of continuous nursing care.

Eighteen days before admission, the child's parents had observed that he had dirt on his mouth while playing beneath a cluster of trees in a nearby yard in a Chicago suburb

Raccoon Roundworm Encephalitis — Continued

where raccoons are common. A field study conducted in September 2000 revealed several sites of raccoon fecal contamination positive for BP eggs in the yard. Infective BP eggs were recovered from soil and debris at the base of the tree cluster; mice infected with these eggs developed fatal encephalitis as a result of NLM.

Los Angeles

In January 2000, a boy aged 17 years with an 8-year history of severe developmental disabilities and geophagia was admitted to a Los Angeles hospital comatose and with generalized hypertonia and hyperreflexia. His mouth was tightly clenched, his eyes wandered rapidly, and he responded only to painful stimuli. Two days before admission, he had a low-grade fever, drowsiness, and problems with coordination. Laboratory findings on admission included peripheral eosinophilia (15% of 15,900 white blood cells/mm^3) and a CSF eosinophilic pleocytosis (37% of 19 white blood cells/mm^3). He was treated with antibacterial, antiviral, antifungal, antiparasitic (albendazole), and antiinflammatory agents, but his condition did not improve. Tests on CSF and blood failed to identify an infectious agent. On examination by a pathologist, a brain biopsy revealed sections of a nematode consistent with *Baylisascaris* species. *Baylisascaris* IFA tested strongly positive with titers of 1:256 in CSF and 1:4,096 in serum specimens. The patient's condition deteriorated and he had progressive, deep white matter abnormalities of the brain on MRI. After a 2-month hospitalization, he was transferred to a long-term–care facility where he remained comatose until he died a year later.

The patient had resided in a group home for developmentally handicapped adolescents and adults in Los Angeles County. In February 2000, a field study conducted in the yard in which the patient regularly played revealed several sites containing raccoon feces; a sample of sandbox soil was positive for BP eggs. Multiple sites in the adjoining yard, to which he also had access, contained raccoon feces with BP eggs.

Reported by: KR Kazacos, DVM, Purdue Univ, West Lafayette, Indiana. PJ Gavin, MD, ST Shulman, MD, TQ Tan, MD, Children's Memorial Hospital and Northwestern Univ Medical School; SI Gerber, MD, Chicago Dept of Public Health, Illinois. WA Kennedy, MD, Harbor-UCLA Medical Center, Torrance; WJ Murray, DVM, San José State Univ, San José; L Mascola, MD, Los Angeles County Dept of Health Svcs, California. Div of Applied Public Health Training, Epidemiology Program Office; Div of Parasitic Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

Editorial Note: Including the two cases in this report, at least 12 cases of severe or fatal BP encephalitis have been identified since 1981 in the United States (California, Illinois, Michigan, Minnesota, New York, Oregon, and Pennsylvania) (*2–8*). Ten of the 12 cases occurred in children aged 9 months–6 years; eight of the children were aged <19 months. Cases of BP ocular larva migrans also have been identified (*2,9*).

Raccoons infected with BP inhabit most of the United States; the highest prevalence of BP infection in raccoons (68%–82%) occurs in the Midwest, Northeast, and on the West coast (*1,2*). Infected raccoons commonly shed millions of BP eggs daily in their feces, and the eggs usually embryonate to the infective stage in 2–4 weeks. The eggs are resistant to most environmental conditions and with adequate moisture can survive for years.

Humans become infected by ingesting infective eggs; from the gastrointestinal tract, the larvae migrate to various somatic tissues, viscera, the eyes, and the central nervous system (CNS). The severity of neurologic disease in humans varies depending on the number of eggs ingested and the number of larvae migrating in the CNS (*1,2*). Larvae in the CNS cause inflammatory reactions and tissue damage and can become encapsulated within granulomas.

Raccoon Roundworm Encephalitis — Continued

A diagnosis of BP encephalitis should be considered in persons, especially children, with sudden onset of eosinophilic encephalitis and a history of potential exposure (e.g., possible ingestion of raccoon feces or contaminated soil). Diagnostic findings include CSF eosinophilic pleocytosis, peripheral eosinophilia, deep white matter abnormalities on MRI, and positive titers on serologic testing of CSF and serum. Because CNS damage can occur before symptom onset, treatment of symptomatic patients with antihelminthic or antiinflammatory drugs often will not improve outcome. Antihelminthic treatment (albendazole, 25–50 mg/kg/d for 10 days) started in 1–3 days of possible infection might prevent clinical disease by killing larvae before they enter the CNS (*2*). Immediate treatment is recommended in cases of probable infection.

The risk for BP infection is greatly reduced by avoiding direct contact with raccoons and their urban habitats, by removing access to food and potential denning sites, and by limiting exposure to areas and materials that might be contaminated by raccoon feces. Raccoons typically defecate at the base of or in raised forks of trees or on raised horizontal surfaces such as fallen logs, stumps, or large rocks. Raccoon feces also can be found on woodpiles, decks, rooftops, and in attics, garages, and haylofts. Feces usually are dark and tubular, have a pungent odor, and often contain undigested food items.

To eliminate BP eggs, feces and contaminated material should be removed carefully and burned, buried, or sent to a landfill, and care should be taken to avoid contamination of hands and clothes. Decks, patios, and other surfaces can be treated with boiling water. Newly deposited eggs take at least 2–4 weeks to become infective; therefore, prompt removal and destruction of raccoon feces will reduce risk for exposure and infection. Additional information about raccoon roundworm is available at http://www.cdc.gov/ncidod/dpd/parasites/baylisacaris/default.htm.

References

1. Kazacos KR, Boyce WM. *Baylisascaris* larva migrans. J Am Vet Med Assoc 1989;195:894–903.
2. Kazacos KR. *Baylisascaris procyonis* and related species. In: Samuel WM, Pybus MJ, Kocan AA, eds. Parasitic diseases of wild mammals. 2nd ed. Ames, Iowa: Iowa State Univ Press, 2001:301–41.
3. Huff DS, Neafie RC, Binder MJ, et al. The first fatal *Baylisascaris* infection in humans: an infant with eosinophilic meningoencephalitis. Pediatr Pathol 1984;2:345–52.
4. Fox AS, Kazacos KR, Gould NS, et al. Fatal eosinophilic meningoencephalitis and visceral larva migrans caused by the raccoon ascarid *Baylisascaris procyonis*. N Engl J Med 1985;312:1619–23.
5. Cunningham CK, Kazacos KR, McMillan JA, et al. Diagnosis and management of *Baylisascaris procyonis* infection in an infant with nonfatal meningoencephalitis. Clin Infect Dis 1994;18:868–72.
6. Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (*Baylisascaris procyonis*) encephalitis: case report and field investigation. Pediatrics 2000;106:e56. Available at http://www.pediatrics.org/cgi/content/full/106/4/e56. Accessed December 2001.
7. Rowley HA, Uht RM, Kazacos KR, et al. Radiologic-pathologic findings in raccoon roundworm (*Baylisascaris procyonis*) encephalitis. Am J Neuroradiol 2000;21:415–20.
8. Moertel CL, Kazacos KR, Butterfield JH, et al. Eosinophil-associated inflammation and elaboration of eosinophil-derived proteins in 2 children with raccoon roundworm (*Baylisascaris procyonis*) encephalitis. Pediatrics 2001;108:e93. Available at http://www.pediatrics.org/cgi/content/full/108/5/e93. Accessed December 2001.
9. Goldberg MA, Kazacos KR, Boyce WM, et al. Diffuse unilateral subacute neuroretinitis: morphometric, serologic, and epidemiologic support for *Baylisascaris* as a causative agent. Ophthalmology 1993;100:1695–701.

Multidrug-Resistant *Streptococcus pneumoniae* in a Child Care Center — Southwest Georgia, December 2000

On December 18, 2000, public health officials in southwest Georgia contacted the Georgia Division of Public Health (GDPH) about a child aged 11 months hospitalized for refractory otitis media. Eight days before hospitalization, a culture of drainage obtained from the child's middle ear revealed *Streptococcus pneumoniae* resistant to penicillin, clindamycin, erythromycin, trimethoprim/sulfamethoxazole, and tetracycline (index strain). The child attended a local child care center. GDPH and CDC conducted an investigation to determine the rate of pneumococcal carriage among attendees of the child care center, to identify risk factors for carriage of the index strain, and to characterize parental knowledge and use of antibiotics and of pneumococcal conjugate vaccine (PCV7) (Prevnar™, Wyeth Lederle Vaccine, Philadelphia, Pennsylvania). GDPH met with parents and physicians of children attending the child care center to discuss the results of the investigation and the importance of vaccination with PCV7. This report summarizes the results of the investigation, which suggest that person-to-person transmission of the index strain had occurred at the child care center and indicate that most parents had been unaware of the dangers of frequent antibiotic use and of the availability of PCV7. A multifaceted intervention targeting parents and health-care providers might improve prescribing practices and vaccination in this community.

The child care center is located in a rural county (1999 population: 6,318) in southwest Georgia and serves approximately 54 children (median age: 26.4 months; age range: 9 months–10 years). The children are divided into two groups on the basis of age (≤18 months and >18 months) and the two groups have separate rooms. After obtaining informed consent from parents of children attending the child care center, nasopharyngeal (NP) swabs were collected, inoculated into skim milk, tryptone, glucose, and glycerol medium (STGG), and sent to CDC for serotyping and susceptibility testing. A case of index-strain carriage was defined as occurrence of *S. pneumoniae* with a susceptibility profile identical to the index-strain profile in a culture from an NP swab of a child who attended the child care center. Parents of children from whom NP swabs were obtained completed a knowledge, attitudes, and practices (KAP) questionnaire. A cross-sectional survey was performed to assess risk factors for pneumococcal carriage.

NP swabs were obtained from five of the 12 children who had shared a room at the child care center with the child who was hospitalized; NP swabs also were obtained from 17 of the 42 children from the other room. One swab was lost during processing. *S. pneumoniae* was isolated from 19 (90%) of the 21 NP cultures; of these 19, a total of 10 (53%) were serotype 14 and had susceptibility profiles that were identical to the index strain. Of the 19 isolates, 15 (79%) were penicillin nonsusceptible (i.e., intermediate or high-level resistance [minimum inhibitory concentration ≥0.12 μg/ml]), and 15 (79%) were resistant to more than one antibiotic or class of antibiotic. Five pneumococcal serotypes were identified: serotype 14 (10), 19F (five), 6B (two), 35B (one), and 33F (one). Of the 19 isolates, 17 were serotypes included in PCV7 (14, 19F, 6B, 4, 9V, 23F, and 18C). Four (40%) of the 10 children with index-strain carriage had shared a room at the child care center with the hospitalized child (index patient).

Sixteen parents completed the questionnaire with one parent responding for each child, accounting for 20 (91%) of the 22 children from whom swabs were obtained. The 10 children carrying the index strain were younger than 10 children not carrying the index strain (mean: aged 19 months versus 30 months; p=0.03). Of 20 children in the child care

Multidrug-Resistant Streptococcus pneumoniae — *Continued*

center, 14 (82%) had an illness for which they received antibiotic treatment during the 2 months preceding the questionnaire. No association was identified between carrying the index strain and having received antibiotics during the preceding 2 months.

Of 16 parents, five (31%) were unaware of the health dangers of frequent antibiotic use, and 10 (63%) were unaware of the availability of PCV7. Among the parents of the seven children aware of the availability of PCV7, three had heard about it from their health-care provider, two from their health department, and two from electronic media (e.g., television and radio).

Because of the high carriage rate of pneumococcus among attendees of the child care center (90%), GDPH recommended that children aged <5 years attending the child care center be vaccinated with PCV7 (*1*). In March 2001, GDPH met with parents and physicians of children attending the child care center to discuss the investigation and the importance of judicious antibiotic use. In addition, treatment guidelines for acute otitis media (AOM) were reviewed with health-care providers, and appropriate therapy for viral infections was reviewed with parents.

Reported by: A Addison, MSN, L Addison, Miller County Health Dept, Colquitt; H Perry, MT, J Jenkins, MPH, Georgia Health District 8-2; S Lance-Parker, DVM, K Arnold, MD, S Kramer, MPH, Notifiable Disease Epidemiology Section, P Blake, MD, State Epidemiologist, Georgia Div of Public Health. Respiratory Disease Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

Editorial Note: *S. pneumoniae* is a leading cause of community-acquired respiratory infection. Asymptomatic nasopharyngeal carriage of pneumococcus is intermittent. Cross-sectional studies suggest that pneumococcus can be found among 15% of adults; in child care settings, up to 65% of children are colonized (*2*). Although pneumococcal carriage can lead to invasive disease (e.g., meningitis or bacteremia), AOM is the most common clinical manifestation of pneumococcal infection among children and the most common outpatient diagnosis resulting in antibiotic prescriptions among children (*1*). Pneumococcal resistance to penicillin and other antibiotics has increased since 1995 (*3*).

In the United States, recent antibiotic use, child care center attendance, and being white are risk factors for carriage of and infection with drug-resistant pneumococcus among children (*4,5*). Of the 21 children from whom NP swabs were collected for culture, 90% were carrying pneumococcus, and approximately half of the isolates were serotype 14 with the same susceptibility pattern as the index strain. The similarity of the 10 isolates obtained from this child care center suggests person-to-person transmission.

PCV7 offers protection against the seven serotypes that most commonly cause invasive disease in children in the United States (*1*). Licensed for use in February 2000, PCV7 is effective in children aged <2 years. Although the efficacy of PCV7 against all AOM episodes is 6%, efficacies against PCV7 serotype-related pneumococcal AOM and invasive pneumococcal disease are 57% and 94%, respectively (*6,7*). Of the pneumococcal isolates carried by children in the child care center, 90% belonged to PCV7-related serotypes. PCV7 became readily available to the community in February 2001, 2 months after the investigation.

The findings in this report are subject to at least two limitations. First, because of the winter holidays, some children who ordinarily attended the child care center were not available for NP culturing. Second, the small sample size limited the ability to draw other conclusions (e.g., an association between recent antibiotic use and drug-resistant pneumococcal carriage).

Multidrug-Resistant Streptococcus pneumoniae — *Continued*

In addition to groups who are recommended to receive PCV7 routinely, the Advisory Committee on Immunization Practices recommends that health-care providers consider PCV7 for children aged 24–59 months who attend group child care centers (*1*). Health-care and child care providers and local health departments should inform parents about the availability of PCV7. Interim recommendations have been published about PCV7 use during the current temporary shortage (*8*). To ensure that vaccine reaches children at highest risk, only children aged <2 years and aged ≥2 years with high-risk medical conditions should receive vaccine until the shortage is resolved.

In the United States, children aged 0–4 years receive approximately half of all outpatient antibiotic prescriptions, and 30% of all antibiotic prescriptions are used to treat presumptive AOM in this age group (*9*). Substantial decreases in overall antibiotic exposure could be achieved through the use of criteria for the diagnosis and treatment of upper respiratory infection, including AOM (*10*). The results of the KAP survey suggest that parents might benefit from improved communication with their health-care providers about appropriate use of antibiotics.

CDC is tracking potential pneumococcal conjugate vaccine failures among children aged <5 years who have had invasive pneumococcal infections (e.g., meningitis or bacteremia) following 1 or more doses of PCV7, and for whom pneumococcal isolates and reliable vaccination information are available. The pneumococcal conjugate vaccine failure report form and instructions on completing the form and sending pneumococcal isolates to CDC are available at http://www.cdc.gov/nip/diseases/pneumo/PCV-survrpts/default.htm.

Information about practices that might prevent person-to-person transmission in child care settings, such as hand washing and group separation of children, is available at http://www.cdc.gov/ncidod/hip/abc/abc.htm. Additional resources are available at http://www.cdc.gov/antibioticresistance.

References

1. CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(no. RR-9).
2. Craig AS, Erwin PC, Schaffner W, et al. Carriage of multidrug-resistant *Streptococcus pneumoniae* and impact of chemoprophylaxis during an outbreak of meningitis at a day care center. Clin Infect Dis 1999;29:1257–64.
3. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. N Engl J Med 2000;343:1917–24.
4. Levine O, Farley M, Harrison L, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatr 1999;103:28.
5. Arnold KE, Leggiadro RJ, Breiman RF, et al. Risk factors for carriage of drug-resistant *Streptococcus pneumoniae* among children in Memphis, Tennessee. J Pediatr 1996;128:757–64.
6. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403–9.
7. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187–95.
8. CDC. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. MMWR 2001;50:1140–2.
9. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998;279:875–7.
10. Dowell S, Marcy S, Phillips W, Gerber M, Schwartz B. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatr 1998;101:163–5.

Notice to Readers

Update: Supply of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine

Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) remains in short supply, and the shortage will continue into mid-2002 (*1*). Shortages are greatest in the public sector. Despite high vaccination rates, pertussis continues to cause serious illness and death, particularly among infants aged <6 months who are too young to have completed the 3-dose primary series of DTaP. In 2000, a total of 1,873 pertussis cases (rate: 99 per 100,000 infants aged <6 months) and 16 deaths were reported among infants aged <6 months. Vaccinating infants on time with the 3-dose primary series of DTaP to protect them from serious disease remains a priority during this vaccine shortage.

The shortage began in 2000 when two manufacturers (Wyeth Lederle, Pearl River, New York, and Baxter Hyland Immuno Vaccines, Baltimore, Maryland) stopped production of DTaP (*1*). Aventis Pasteur (Swiftwater, Pennsylvania) and GlaxoSmithKline (Philadelphia, Pennsylvania), producers of Tripedia® and Infanrix™, respectively, are the only two U.S. suppliers.

DTaP is recommended as a 5-dose series: 3 doses administered to infants at ages 2, 4, and 6 months, followed by 2 additional doses at age 15–18 months and at age 4–6 years (*2*). During the shortage of DTaP, the Advisory Committee on Immunization Practices recommends that providers who do not have enough DTaP to vaccinate all children with 5 doses give priority to vaccinating infants with the first 3 doses. To ensure an adequate supply of DTaP to vaccinate infants, providers should first defer vaccination of children aged 15–18 months with the fourth DTaP dose. If deferring the fourth dose does not leave enough DTaP to vaccinate infants, then the fifth DTaP dose (given to children aged 4–6 years) also should be deferred*. In areas with severe DTaP shortages, local public health officials might elect to recommend communitywide deferral of the fourth DTaP dose, and, if necessary, the fifth DTaP dose.

When the DTaP shortage ends, providers should recall and administer DTaP to all children who missed a dose. Vaccination of children aged 4–6 years is needed to ensure immunity to pertussis, diphtheria, and tetanus during the elementary school years (*2*).

References

1. CDC. Update on the supply of tetanus and diphtheria toxoids and of tetanus and diphtheria toxoids and acellular pertussis vaccine. MMWR 2001;50:189–90.
2. CDC. Pertussis vaccination: use of acellular pertussis vaccine among infants and young children—recommendations of the Advisory Committee on Immunization Practices. MMWR 1997;46(no. RR-7).
3. CDC. Recommended childhood immunization schedule—United States, 2001. MMWR 2001;50:7–10,19.

*Children traveling to countries where the risk for diphtheria is high should be vaccinated according to the Recommended Childhood Immunization Schedule (*3*). Travelers might be at increased risk for exposure to toxigenic strains of *Corynebacterium diphtheriae*, especially with prolonged travel, extensive contact with children, or exposure to poor hygiene. High-risk countries include *Africa*—Algeria, Egypt, and sub-Saharan Africa; *Americas*—Brazil, Dominican Republic, Ecuador, and Haiti; *Asia/Oceania*—Afghanistan, Bangladesh, Cambodia, China, India, Indonesia, Iran, Iraq, Laos, Mongolia, Myanmar, Nepal, Pakistan, Philippines, Syria, Thailand, Turkey, Vietnam, and Yemen; and *Europe*—Albania and all countries of the former Soviet Union.

Notices to Readers — Continued

Notice to Readers

Epi Info 2000: A Course for Teachers of Epidemiologic Computing

CDC and Emory University's Rollins School of Public Health will co-sponsor a course, "Epi Info 2000: A Course for Teachers of Epidemiologic Computing" during March 11–14, 2002, at Emory University. The course is designed for teachers of epidemiologic computing with intermediate to advanced skills in computing.

The 4-day course provides hands-on experience with the new Windows® version of Epi Info, programming Epi Info software at the intermediate to advanced level, methods of teaching epidemiologic computing, computerized interactive exercises for teaching epidemiology, and computing. There is a tuition charge.

Application deadline is February 1. Additional information and applications are available at http://www.sph.emory.edu/EPICOURSES or by e-mail: pvaleri@sph.emory.edu.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending December 22, 2001, with historical data



* No measles or rubella cases were reported for the current 4-week period yielding a ratio for week 51 of zero (0).

† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending December 22, 2001 (51st Week)*

	Cum. 2001		Cum. 2001
Anthrax	15	Poliomyelitis, paralytic	-
Brucellosis†	91	Psittacosis†	27
Cholera	4	Q fever†	22
Cyclosporiasis†	127	Rabies, human	1
Diphtheria	2	Rocky Mountain spotted fever (RMSF)	604
Ehrlichiosis: human granulocytic (HGE)†	215	Rubella, congenital syndrome	2
human monocytic (HME)†	97	Streptococcal disease, invasive, group A	3,673
Encephalitis: California serogroup viral†	103	Streptococcal toxic-shock syndrome†	55
eastern equine†	8	Syphilis, congenital¶	240
St. Louis†	3	Tetanus	27
western equine†	-	Toxic-shock syndrome	124
Hansen disease (leprosy)†	88	Trichinosis	25
Hantavirus pulmonary syndrome†	6	Tularemia†	104
Hemolytic uremic syndrome, postdiarrheal†	161	Typhoid fever	316
HIV infection, pediatric†§	200	Yellow fever	-
Plague	2		

-: No reported cases.
*Incidence data for reporting year 2001 are provisional and cumulative (year-to-date).
† Not notifiable in all states.
§ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last updated November 27, 2001.
¶ Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	AIDS		Chlamydia§		Cryptosporidiosis		*Escherichia coli* O157:H7†			
							NETSS		PHLIS	
	Cum. 2001¶	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	37,411	37,591	701,186	681,066	3,465	2,936	3,086	4,432	2,237	3,601
NEW ENGLAND	1,403	2,000	22,678	23,081	128	139	224	377	228	380
Maine	44	40	1,299	1,440	18	20	27	31	27	29
N.H.	37	30	1,327	1,103	17	24	36	39	31	38
Vt.	15	38	622	520	34	28	14	37	10	37
Mass.	704	1,188	9,855	9,982	51	37	115	166	112	174
R.I.	95	91	2,831	2,577	8	4	17	20	11	18
Conn.	508	613	6,744	7,459	-	26	15	84	37	84
MID. ATLANTIC	9,346	8,235	82,142	65,055	299	383	252	435	181	346
Upstate N.Y.	945	676	15,204	3,746	111	130	160	295	136	82
N.Y. City	5,253	4,090	28,464	25,737	107	170	14	23	11	18
N.J.	1,607	1,799	12,901	10,443	26	19	78	117	34	117
Pa.	1,541	1,670	25,573	25,129	55	64	N	N	-	129
E.N. CENTRAL	2,812	3,468	115,711	117,921	1,484	953	790	1,085	505	752
Ohio	538	578	24,318	30,864	187	259	230	271	155	225
Ind.	343	347	14,805	13,336	81	59	85	125	43	88
Ill.	1,255	1,695	32,354	32,560	433	122	161	193	135	157
Mich.	500	648	29,637	25,112	179	95	100	141	82	104
Wis.	176	200	14,597	16,049	604	418	214	355	90	178
W.N. CENTRAL	808	861	35,248	38,707	518	351	562	665	457	624
Minn.	133	160	7,049	8,008	185	123	274	205	212	231
Iowa	85	83	4,611	5,262	81	76	79	180	62	148
Mo.	405	413	12,882	13,155	45	31	61	110	94	98
N. Dak.	2	3	874	875	13	16	18	21	34	21
S. Dak.	23	7	1,751	1,818	8	15	43	56	41	59
Nebr.	68	68	2,220	3,681	182	81	60	63	-	49
Kans.	92	127	5,861	5,908	4	9	27	30	14	18
S. ATLANTIC	11,517	10,647	131,588	128,203	336	471	240	368	149	290
Del.	231	220	2,511	2,811	6	6	4	3	7	1
Md.	1,698	1,388	12,162	14,120	40	14	28	34	1	2
D.C.	782	784	3,048	3,119	13	18	-	1	U	U
Va.	911	817	17,358	15,338	27	20	50	75	42	67
W. Va.	95	58	2,257	2,105	2	3	10	15	8	13
N.C.	845	673	19,799	21,405	31	28	57	90	43	73
S.C.	645	761	10,506	9,740	7	-	23	21	11	16
Ga.	1,528	1,120	28,739	27,257	132	170	33	41	15	39
Fla.	4,782	4,826	35,208	32,308	78	212	35	88	22	79
E.S. CENTRAL	1,671	1,959	48,003	50,575	51	50	132	150	112	118
Ky.	315	210	8,267	7,998	4	7	58	40	49	32
Tenn.	540	838	14,976	14,846	16	11	46	61	48	55
Ala.	415	482	13,824	15,209	18	16	18	10	6	9
Miss.	401	429	10,936	12,522	13	16	10	39	9	22
W.S. CENTRAL	3,856	3,850	100,765	101,236	120	162	113	224	91	282
Ark.	189	193	6,695	6,205	8	16	14	56	-	38
La.	806	662	16,602	17,676	7	14	4	15	26	54
Okla.	214	354	10,078	9,277	15	17	34	19	28	17
Tex.	2,647	2,641	67,390	68,078	90	115	61	134	37	173
MOUNTAIN	1,288	1,355	41,204	36,888	239	174	288	423	171	305
Mont.	15	16	1,849	1,438	37	10	20	31	-	-
Idaho	19	22	1,882	1,861	23	23	76	73	39	41
Wyo.	4	10	818	779	7	5	7	21	1	11
Colo.	267	326	10,391	9,157	43	72	88	156	54	110
N. Mex.	137	140	5,767	5,170	29	22	16	22	11	18
Ariz.	502	410	14,146	12,322	11	10	31	56	23	44
Utah	110	148	1,870	2,187	83	28	32	49	42	71
Nev.	234	283	4,481	3,974	6	4	18	15	1	10
PACIFIC	4,710	5,216	123,847	119,400	290	253	485	705	343	504
Wash.	483	463	13,361	12,862	7	U	131	223	62	206
Oreg.	213	170	7,300	6,939	53	20	82	134	61	114
Calif.	3,898	4,445	96,885	93,625	226	233	249	302	211	167
Alaska	18	23	2,605	2,469	1	-	4	32	1	6
Hawaii	98	115	3,696	3,505	3	-	19	14	8	11
Guam	12	13	-	490	-	-	N	N	U	U
P.R.	1,113	1,298	2,404	U	-	-	1	7	U	U
V.I.	11	34	53	-	-	-	-	-	U	U
Amer. Samoa	1	-	U	U	U	U	U	U	U	U
C.N.M.I.	-	-	129	U	-	U	-	U	U	U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

§ Chlamydia refers to genital infections caused by *C. trachomatis*.

¶ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last updated November 27, 2001.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	Gonorrhea		Hepatitis C; Non-A, Non-B		Legionellosis		Listeriosis	Lyme Disease	
	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	321,763	348,858	3,199	3,073	1,065	1,059	529	13,208	16,840
NEW ENGLAND	6,517	6,498	32	33	73	56	45	3,911	5,495
Maine	141	88	-	2	8	2	2	-	-
N.H.	180	108	-	-	12	4	4	114	69
Vt.	73	64	7	4	5	5	3	17	40
Mass.	3,092	2,743	25	21	21	18	26	826	1,156
R.I.	813	636	-	6	13	9	2	493	611
Conn.	2,218	2,859	-	-	14	18	8	2,461	3,619
MID. ATLANTIC	41,430	38,713	1,598	643	231	296	89	6,996	8,754
Upstate N.Y.	8,776	7,277	58	39	70	95	29	3,607	3,906
N.Y. City	12,183	11,468	-	-	39	47	18	10	177
N.J.	7,624	7,011	1,473	561	25	23	25	1,854	2,453
Pa.	12,847	12,957	67	43	97	131	17	1,525	2,218
E.N. CENTRAL	60,482	70,218	160	226	312	279	75	677	770
Ohio	13,607	19,032	9	12	149	116	17	113	60
Ind.	6,732	6,246	1	-	25	37	8	23	23
Ill.	18,074	20,392	14	21	19	33	16	22	35
Mich.	16,714	17,667	136	193	83	50	24	17	23
Wis.	5,355	6,881	-	-	36	43	10	502	629
W.N. CENTRAL	15,060	17,592	747	617	49	58	21	400	425
Minn.	2,285	3,129	12	7	9	7	3	332	322
Iowa	1,224	1,264	-	2	8	15	2	36	33
Mo.	7,905	8,671	715	594	23	26	10	26	46
N. Dak.	40	71	-	1	1	-	-	-	2
S. Dak.	278	275	-	-	3	2	-	-	-
Nebr.	713	1,495	8	4	4	4	1	4	5
Kans.	2,615	2,687	12	9	1	4	5	2	17
S. ATLANTIC	80,950	90,371	112	112	202	190	75	941	1,125
Del.	1,545	1,713	7	2	12	10	2	151	167
Md.	6,904	9,654	17	14	37	68	16	550	661
D.C.	2,727	2,634	-	3	8	7	-	17	11
Va.	10,428	10,174	2	3	28	34	13	118	146
W. Va.	701	635	9	20	N	N	5	13	34
N.C.	15,578	17,426	21	20	11	16	6	41	46
S.C.	6,943	8,265	6	3	14	6	5	7	21
Ga.	15,889	17,812	1	3	10	7	14	-	-
Fla.	20,235	22,058	49	44	82	42	14	44	39
E.S. CENTRAL	31,235	36,214	180	448	56	40	21	63	50
Ky.	3,345	3,481	9	38	11	20	5	22	13
Tenn.	9,863	11,702	66	100	30	12	9	30	28
Ala.	10,829	11,944	5	10	13	5	7	10	6
Miss.	7,198	9,087	100	300	2	3	-	1	3
W.S. CENTRAL	49,294	53,505	179	734	13	26	29	82	90
Ark.	4,162	3,628	4	9	-	-	1	1	5
La.	11,428	13,113	90	451	2	7	-	2	8
Okla.	4,587	4,191	4	10	3	5	2	-	1
Tex.	29,117	32,573	81	264	8	14	26	79	76
MOUNTAIN	9,805	10,288	60	80	60	43	38	13	14
Mont.	101	57	1	5	-	2	-	-	-
Idaho	72	95	2	3	3	5	1	5	4
Wyo.	78	51	9	2	1	-	2	1	3
Colo.	2,914	3,107	13	17	19	15	10	1	-
N. Mex.	969	1,144	12	16	3	1	7	1	-
Ariz.	3,865	4,072	9	20	23	7	9	2	-
Utah	142	231	3	1	7	12	2	1	3
Nev.	1,664	1,531	11	16	4	1	7	2	4
PACIFIC	26,990	25,459	131	180	69	71	136	125	117
Wash.	2,940	2,341	23	34	10	18	10	8	9
Oreg.	1,124	1,020	13	26	N	N	9	13	13
Calif.	21,935	21,270	95	118	55	52	111	102	93
Alaska	426	351	-	-	-	-	-	2	2
Hawaii	565	477	-	2	4	1	6	N	N
Guam	-	54	-	3	-	-	-	-	-
P.R.	578	513	1	1	2	1	-	N	N
V.I.	6	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	-	U	U
C.N.M.I.	14	U	-	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	Malaria		Rabies, Animal		Salmonellosis†			
					NETSS		PHLIS	
	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	1,251	1,453	6,472	6,812	37,242	38,156	28,019	31,613
NEW ENGLAND	88	71	725	810	2,292	2,146	2,124	2,186
Maine	5	6	69	130	166	124	151	101
N.H.	2	1	21	21	163	145	155	146
Vt.	1	4	61	57	82	109	71	104
Mass.	38	32	271	275	1,301	1,218	1,116	1,235
R.I.	13	8	70	57	139	142	173	158
Conn.	29	20	233	270	441	408	458	442
MID. ATLANTIC	380	384	1,181	1,279	4,968	4,919	3,648	5,210
Upstate N.Y.	69	75	768	816	1,261	1,214	1,213	1,270
N.Y. City	201	225	35	18	1,076	1,176	1,357	1,274
N.J.	76	49	190	194	1,598	1,132	657	1,010
Pa.	34	35	188	251	1,033	1,397	421	1,656
E.N. CENTRAL	141	148	143	169	4,828	5,298	4,101	3,657
Ohio	27	22	52	52	1,359	1,580	1,165	1,446
Ind.	16	8	15	14	525	627	482	606
Ill.	35	66	24	22	1,306	1,459	1,169	290
Mich.	42	33	46	69	828	887	791	933
Wis.	21	19	6	12	810	745	494	382
W.N. CENTRAL	35	68	363	531	2,313	2,360	2,328	2,484
Minn.	6	27	46	94	672	530	665	665
Iowa	9	2	82	78	339	361	301	349
Mo.	13	21	40	50	637	709	940	853
N. Dak.	-	2	41	115	60	63	84	76
S. Dak.	-	1	56	96	147	98	118	102
Nebr.	2	8	4	2	153	223	-	139
Kans.	5	7	94	96	305	376	220	300
S. ATLANTIC	286	336	2,241	2,351	8,804	8,009	5,912	5,842
Del.	2	5	30	49	86	117	112	130
Md.	111	125	338	412	818	786	853	717
D.C.	13	17	-	-	81	63	U	U
Va.	49	50	485	559	1,310	993	1,041	923
W. Va.	1	4	137	114	140	166	140	152
N.C.	19	36	569	563	1,368	1,137	1,219	1,124
S.C.	8	2	114	155	894	739	723	570
Ga.	30	30	399	340	1,660	1,465	1,210	1,705
Fla.	53	67	169	159	2,447	2,543	614	521
E.S. CENTRAL	34	47	200	205	2,607	2,428	1,788	1,805
Ky.	12	18	27	21	366	382	230	267
Tenn.	12	12	105	104	647	676	788	803
Ala.	6	16	64	79	746	672	474	599
Miss.	4	1	4	1	848	698	296	136
W.S. CENTRAL	12	73	1,045	867	4,026	4,907	2,537	3,000
Ark.	3	3	20	20	887	717	92	577
La.	5	14	3	4	424	875	952	751
Okla.	3	10	60	57	479	393	375	298
Tex.	1	46	962	786	2,236	2,922	1,118	1,374
MOUNTAIN	63	52	231	291	2,187	2,729	1,801	2,471
Mont.	3	1	38	65	73	96	-	-
Idaho	4	4	28	9	144	130	95	118
Wyo.	-	-	20	77	55	73	52	60
Colo.	23	25	-	-	586	687	577	666
N. Mex.	3	-	14	21	280	235	235	206
Ariz.	17	9	115	100	659	763	627	761
Utah	4	6	15	10	215	481	192	478
Nev.	9	7	1	9	175	264	23	182
PACIFIC	212	274	343	309	5,217	5,360	3,780	4,958
Wash.	15	33	-	-	546	573	491	672
Oreg.	14	39	3	7	240	287	309	357
Calif.	172	192	300	270	4,021	4,213	2,622	3,652
Alaska	1	-	40	32	50	59	28	36
Hawaii	10	10	-	-	360	228	330	241
Guam	-	2	-	-	-	27	U	U
P.R.	5	5	90	78	556	690	U	U
V.I.	-	-	-	-	-	-	U	U
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	16	U	U	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	Shigellosis† NETSS Cum. 2001	Shigellosis† NETSS Cum. 2000	Shigellosis† PHLIS Cum. 2001	Shigellosis† PHLIS Cum. 2000	Syphilis (Primary & Secondary) Cum. 2001	Syphilis (Primary & Secondary) Cum. 2000	Tuberculosis Cum. 2001	Tuberculosis Cum. 2000
UNITED STATES	18,126	22,021	7,747	12,555	5,720	5,863	12,089	14,474
NEW ENGLAND	272	404	276	382	68	84	404	449
Maine	6	11	3	11	1	1	3	23
N.H.	7	7	4	8	1	2	17	21
Vt.	7	4	6	-	3	-	4	4
Mass.	199	282	185	262	43	61	240	265
R.I.	23	33	26	34	9	4	39	32
Conn.	30	67	52	67	11	16	101	104
MID. ATLANTIC	1,388	2,762	724	1,709	488	274	2,241	2,256
Upstate N.Y.	474	786	113	212	28	12	347	323
N.Y. City	352	935	362	627	269	116	1,124	1,184
N.J.	366	502	184	431	142	70	486	541
Pa.	196	539	65	439	49	76	284	208
E.N. CENTRAL	4,320	4,090	1,837	1,300	1,006	1,185	1,351	1,485
Ohio	2,974	437	1,182	322	76	68	273	313
Ind.	223	1,510	50	155	159	346	109	139
Ill.	537	1,161	362	167	352	412	624	692
Mich.	300	656	216	600	397	314	265	256
Wis.	286	326	27	56	22	45	80	85
W.N. CENTRAL	1,960	2,453	1,267	2,039	85	64	444	515
Minn.	452	795	440	908	28	16	226	167
Iowa	364	535	290	348	4	11	34	36
Mo.	305	660	218	463	22	29	135	192
N. Dak.	22	51	35	51	-	-	4	5
S. Dak.	643	8	246	6	1	-	13	16
Nebr.	98	151	-	117	5	2	32	23
Kans.	76	253	38	146	25	6	-	76
S. ATLANTIC	2,751	2,945	841	1,156	1,897	1,956	2,554	2,899
Del.	17	24	14	23	12	8	15	14
Md.	159	198	91	114	249	304	228	246
D.C.	53	80	U	U	41	37	51	37
Va.	599	447	268	349	105	126	256	265
W. Va.	8	22	10	17	4	3	28	33
N.C.	354	389	170	264	426	471	394	447
S.C.	250	136	123	93	222	228	189	280
Ga.	447	256	130	189	366	378	441	612
Fla.	864	1,393	35	107	472	401	952	965
E.S. CENTRAL	1,565	1,187	608	577	646	860	792	912
Ky.	716	518	327	117	45	85	111	120
Tenn.	113	343	120	376	324	519	291	343
Ala.	210	98	130	77	143	121	265	303
Miss.	526	228	31	7	134	135	125	146
W.S. CENTRAL	2,391	3,472	1,146	1,148	739	817	800	2,110
Ark.	537	219	155	61	45	103	150	173
La.	149	290	166	194	168	208	-	310
Okla.	108	124	36	44	66	116	138	142
Tex.	1,597	2,839	789	849	460	390	512	1,485
MOUNTAIN	992	1,254	708	861	228	220	512	549
Mont.	8	8	-	-	-	-	14	17
Idaho	40	44	15	25	1	1	8	10
Wyo.	3	5	5	3	1	1	3	4
Colo.	245	266	258	218	22	11	120	88
N. Mex.	121	184	79	117	17	16	25	43
Ariz.	444	546	290	348	171	185	240	246
Utah	64	81	53	84	8	1	33	48
Nev.	67	120	8	66	8	5	69	93
PACIFIC	2,487	3,454	340	3,383	563	403	2,991	3,299
Wash.	213	455	167	408	54	66	224	247
Oreg.	94	164	111	109	13	12	108	102
Calif.	2,112	2,790	-	2,830	484	323	2,470	2,715
Alaska	7	7	6	3	-	-	50	102
Hawaii	61	38	56	33	12	2	139	133
Guam	-	45	U	U	-	3	-	51
P.R.	9	35	U	U	257	167	76	152
V.I.	-	-	U	U	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	8	U	U	U	13	U	32	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	*H. influenzae*, Invasive		Hepatitis (Viral), By Type				Measles (Rubeola)					
			A		B		Indigenous		Imported†		Total	
	Cum. 2001§	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	1,383	1,264	10,432	12,797	6,565	6,961	-	61	-	47	108	80
NEW ENGLAND	93	110	661	389	95	117	-	4	-	1	5	6
Maine	2	2	11	21	5	5	-	-	-	-	-	-
N.H.	7	12	18	19	16	19	-	-	-	-	-	3
Vt.	5	10	16	10	4	6	-	1	-	-	1	3
Mass.	41	44	311	136	11	15	-	2	-	1	3	-
R.I.	7	4	72	25	28	24	-	-	-	-	-	-
Conn.	31	38	233	178	31	48	-	1	-	-	1	-
MID. ATLANTIC	231	230	1,185	1,498	1,163	1,135	-	5	-	11	16	24
Upstate N.Y.	77	101	275	251	133	139	-	1	-	4	5	10
N.Y. City	50	60	304	516	447	547	-	3	-	1	4	13
N.J.	81	41	401	287	338	179	-	-	-	1	1	-
Pa.	23	28	205	444	245	270	-	1	-	5	6	1
E.N. CENTRAL	227	177	1,199	1,649	897	740	-	-	-	10	10	8
Ohio	74	54	261	264	93	105	-	-	-	3	3	2
Ind.	51	30	102	117	48	49	-	-	-	4	4	-
Ill.	63	59	445	683	152	124	-	-	-	3	3	3
Mich.	13	11	322	486	604	420	-	-	-	-	-	3
Wis.	26	23	69	99	-	42	U	-	U	-	-	-
W.N. CENTRAL	72	78	404	646	213	298	-	4	-	1	5	3
Minn.	46	43	42	173	31	42	-	2	-	1	3	1
Iowa	-	-	36	66	21	34	-	-	-	-	-	-
Mo.	16	23	105	254	109	147	-	2	-	-	2	-
N. Dak.	7	4	3	4	2	2	-	-	-	-	-	-
S. Dak.	-	1	3	3	1	2	-	-	-	-	-	-
Nebr.	2	3	35	37	28	44	U	-	U	-	-	-
Kans.	1	4	180	109	21	27	-	-	-	-	-	2
S. ATLANTIC	380	277	2,503	1,456	1,499	1,268	-	4	-	1	5	4
Del.	-	-	15	15	11	15	-	-	-	-	-	-
Md.	92	78	317	207	141	123	-	2	-	1	3	-
D.C.	-	-	73	35	13	34	-	-	-	-	-	-
Va.	28	39	135	154	181	165	-	1	-	-	1	2
W. Va.	16	8	27	56	25	25	U	-	U	-	-	-
N.C.	49	23	240	150	214	250	-	-	-	-	-	-
S.C.	9	7	75	86	30	23	-	-	-	-	-	-
Ga.	104	71	969	288	463	222	-	1	-	-	1	-
Fla.	82	51	652	465	421	411	-	-	-	-	-	2
E.S. CENTRAL	76	52	405	408	431	479	-	2	-	-	2	-
Ky.	2	12	127	61	45	80	-	2	-	-	2	-
Tenn.	44	24	169	148	244	220	-	-	-	-	-	-
Ala.	28	14	79	56	88	71	-	-	-	-	-	-
Miss.	2	2	30	143	54	108	U	-	U	-	-	-
W.S. CENTRAL	52	63	1,310	2,395	670	1,074	-	-	-	1	1	1
Ark.	2	2	67	132	98	96	U	-	U	-	-	1
La.	6	16	61	106	48	152	U	-	U	-	-	-
Okla.	43	43	117	255	107	152	-	-	-	-	-	-
Tex.	1	2	1,065	1,902	417	674	-	-	-	1	1	-
MOUNTAIN	142	131	743	949	487	546	-	2	-	-	2	12
Mont.	-	1	12	7	3	7	U	-	U	-	-	-
Idaho	2	4	57	43	11	10	-	1	-	-	1	-
Wyo.	-	1	7	4	3	3	-	-	-	-	-	-
Colo.	38	33	89	221	103	106	-	-	-	-	-	2
N. Mex.	27	26	37	70	131	139	-	-	-	-	-	-
Ariz.	56	49	410	457	161	201	-	1	-	-	1	-
Utah	8	11	69	62	27	28	U	-	U	-	-	3
Nev.	11	6	62	85	48	52	-	-	-	-	-	7
PACIFIC	110	146	2,022	3,407	1,110	1,304	-	40	-	22	62	22
Wash.	7	8	160	279	140	110	-	13	-	2	15	3
Oreg.	22	33	78	170	117	119	-	4	-	-	4	-
Calif.	51	35	1,767	2,932	826	1,050	-	21	-	15	36	15
Alaska	6	45	14	13	9	13	-	-	-	-	-	1
Hawaii	24	25	3	13	18	12	-	2	-	5	7	3
Guam	-	3	-	1	-	10	U	-	U	-	-	-
P.R.	1	4	132	247	188	290	U	-	U	-	-	2
V.I.	-	-	-	-	-	-	U	-	U	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	35	U	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† For imported measles, cases include only those resulting from importation from other countries.

§ Of 282 cases among children aged <5 years, serotype was reported for 132, and of those, 21 were type b.

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 22, 2001, and December 23, 2000 (51st Week)*

Reporting Area	Meningococcal Disease		Mumps			Pertussis			Rubella		
	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000
UNITED STATES	2,226	2,125	7	226	316	241	5,177	7,122	-	20	166
NEW ENGLAND	114	119	-	-	5	8	492	1,888	-	-	12
Maine	7	8	-	-	-	-	21	45	-	-	-
N.H.	14	12	-	-	-	-	39	127	-	-	2
Vt.	7	4	-	-	-	8	76	253	-	-	-
Mass.	55	68	-	-	1	-	333	1,392	-	-	8
R.I.	6	9	-	-	1	-	6	25	-	-	1
Conn.	25	18	-	-	3	-	17	46	-	-	1
MID. ATLANTIC	255	253	1	24	30	25	305	708	-	5	10
Upstate N.Y.	64	75	1	4	12	9	148	345	-	1	1
N.Y. City	42	45	-	12	8	-	49	90	-	3	9
N.J.	93	53	-	4	3	-	22	36	-	1	-
Pa.	56	80	-	4	7	16	86	237	-	-	-
E.N. CENTRAL	324	384	-	20	24	25	738	870	-	2	1
Ohio	92	94	-	1	8	19	326	366	-	-	-
Ind.	42	46	-	3	2	5	96	127	-	-	-
Ill.	72	87	-	11	6	-	80	115	-	2	1
Mich.	70	114	-	5	6	1	138	127	-	-	-
Wis.	48	43	U	-	2	U	98	135	U	-	-
W.N. CENTRAL	163	150	1	17	19	23	432	639	-	3	2
Minn.	26	21	-	5	-	19	207	395	-	-	1
Iowa	31	35	-	1	8	3	76	59	-	1	-
Mo.	55	67	-	4	5	-	102	97	-	1	-
N. Dak.	6	2	-	-	1	-	5	7	-	-	-
S. Dak.	5	6	-	-	-	1	5	11	-	-	-
Nebr.	25	7	U	1	2	U	7	28	U	-	1
Kans.	15	12	1	6	3	-	30	42	-	1	-
S. ATLANTIC	367	289	1	42	46	87	352	512	-	6	112
Del.	5	1	-	-	-	-	-	9	-	-	1
Md.	41	27	-	7	9	2	45	130	-	-	-
D.C.	-	-	-	-	-	-	1	3	-	-	-
Va.	40	42	-	8	11	84	141	116	-	-	-
W. Va.	14	14	U	-	-	U	4	1	U	-	-
N.C.	63	38	-	5	7	1	74	110	-	-	82
S.C.	35	26	-	7	11	-	34	40	-	2	27
Ga.	52	46	-	7	2	-	27	40	-	1	-
Fla.	117	95	1	8	6	-	26	63	-	3	2
E.S. CENTRAL	133	134	-	9	7	2	162	119	-	-	6
Ky.	23	26	-	3	1	-	59	60	-	-	1
Tenn.	60	57	-	1	2	2	62	35	-	-	1
Ala.	34	36	-	-	4	-	37	20	-	-	4
Miss.	16	15	U	5	-	U	4	4	U	-	-
W.S. CENTRAL	339	229	-	14	35	6	535	363	-	2	8
Ark.	20	14	U	1	3	U	45	37	U	-	1
La.	66	45	U	2	5	U	3	21	U	-	1
Okla.	32	28	-	-	-	3	33	50	-	-	-
Tex.	221	142	-	11	27	3	454	255	-	2	6
MOUNTAIN	96	102	1	15	22	60	1,400	828	-	-	2
Mont.	4	6	U	1	1	U	37	35	U	-	-
Idaho	8	7	1	2	1	-	171	64	-	-	-
Wyo.	5	2	-	2	1	-	1	4	-	-	-
Colo.	36	34	-	3	1	16	336	474	-	-	1
N. Mex.	11	11	-	2	1	-	144	91	-	-	-
Ariz.	16	30	-	1	4	44	595	112	-	-	1
Utah	8	7	U	1	7	U	76	33	U	-	-
Nev.	8	5	-	3	6	-	40	15	-	-	-
PACIFIC	435	465	3	85	128	5	761	1,195	-	2	13
Wash.	65	62	-	2	10	4	170	416	-	-	7
Oreg.	44	70	N	N	N	1	52	108	-	-	-
Calif.	310	316	3	46	87	-	495	609	-	1	6
Alaska	3	9	-	1	8	-	11	21	-	-	-
Hawaii	13	8	-	36	23	-	33	41	-	1	-
Guam	-	-	U	-	16	U	-	4	U	-	1
P.R.	5	10	U	-	-	U	2	10	U	-	-
V.I.	-	-	U	-	-	U	-	-	U	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	U	-	U	U	-	U	U	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

TABLE IV. Deaths in 122 U.S. cities,* week ending December 22, 2001 (51st Week)

Reporting Area	All Causes, By Age (Years)						P&I† Total
	All Ages	≥65	45-64	25-44	1-24	<1	
NEW ENGLAND	271	199	51	15	5	1	29
Boston, Mass.	U	U	U	U	U	U	U
Bridgeport, Conn.	31	20	8	1	2	-	3
Cambridge, Mass.	19	17	1	1	-	-	1
Fall River, Mass.	23	20	2	1	-	-	3
Hartford, Conn.	U	U	U	U	U	U	U
Lowell, Mass.	24	17	2	4	1	-	2
Lynn, Mass.	5	4	1	-	-	-	1
New Bedford, Mass.	U	U	U	U	U	U	U
New Haven, Conn.	37	24	10	2	1	-	2
Providence, R.I.	U	U	U	U	U	U	U
Somerville, Mass.	7	6	1	-	-	-	1
Springfield, Mass.	40	28	9	3	-	-	3
Waterbury, Conn.	14	11	2	-	1	-	2
Worcester, Mass.	71	52	15	3	-	1	11
MID. ATLANTIC	2,221	1,504	438	203	42	32	102
Albany, N.Y.	50	31	10	5	-	4	3
Allentown, Pa.	19	18	-	1	-	-	1
Buffalo, N.Y.	67	42	17	4	2	2	7
Camden, N.J.	26	12	9	2	2	1	4
Elizabeth, N.J.	12	11	1	-	-	-	-
Erie, Pa.§	44	38	3	2	1	-	1
Jersey City, N.J.	31	19	11	-	-	1	-
New York City, N.Y.	1,201	813	255	97	23	11	40
Newark, N.J.	U	U	U	U	U	U	U
Paterson, N.J.	19	9	5	3	-	2	1
Philadelphia, Pa.	409	233	90	66	12	8	19
Pittsburgh, Pa.§	21	6	6	7	1	1	3
Reading, Pa.	26	19	4	3	-	-	1
Rochester, N.Y.	123	102	15	5	-	1	9
Schenectady, N.Y.	22	16	1	5	-	-	1
Scranton, Pa.§	20	18	1	1	-	-	1
Syracuse, N.Y.	87	80	4	1	1	1	8
Trenton, N.J.	22	17	4	1	-	-	2
Utica, N.Y.	22	20	2	-	-	-	1
Yonkers, N.Y.	U	U	U	U	U	U	U
E.N. CENTRAL	1,645	1,158	302	117	31	37	112
Akron, Ohio	62	44	8	5	2	3	8
Canton, Ohio	35	30	5	-	-	-	6
Chicago, Ill.	U	U	U	U	U	U	U
Cincinnati, Ohio	98	72	15	6	1	4	11
Cleveland, Ohio	137	91	26	15	1	4	8
Columbus, Ohio	198	139	30	20	4	5	5
Dayton, Ohio	116	97	14	4	1	-	3
Detroit, Mich.	220	128	57	21	7	7	19
Evansville, Ind.	46	36	8	2	-	-	3
Fort Wayne, Ind.	57	42	9	3	2	1	-
Gary, Ind.	15	10	2	2	1	-	1
Grand Rapids, Mich.	55	38	10	4	1	2	10
Indianapolis, Ind.	252	168	56	17	6	5	14
Lansing, Mich.	U	U	U	U	U	U	U
Milwaukee, Wis.	86	63	14	4	1	4	8
Peoria, Ill.	54	39	11	4	-	-	5
Rockford, Ill.	57	41	12	3	1	-	4
South Bend, Ind.	U	U	U	U	U	U	U
Toledo, Ohio	86	67	11	4	3	1	5
Youngstown, Ohio	71	53	14	3	-	1	2
W.N. CENTRAL	802	569	135	53	29	16	56
Des Moines, Iowa	81	63	12	5	1	-	10
Duluth, Minn.	37	30	6	-	1	-	3
Kansas City, Kans.	35	20	5	8	2	-	-
Kansas City, Mo.	93	65	13	8	4	3	7
Lincoln, Nebr.	55	44	8	1	2	-	5
Minneapolis, Minn.	119	86	20	6	6	1	7
Omaha, Nebr.	76	59	12	3	1	1	6
St. Louis, Mo.	123	73	28	9	6	7	-
St. Paul, Minn.	97	74	12	5	3	3	12
Wichita, Kans.	86	55	19	8	3	1	6
S. ATLANTIC	1,148	732	242	116	32	26	56
Atlanta, Ga.	154	96	30	15	7	6	-
Baltimore, Md.	223	126	61	26	7	3	21
Charlotte, N.C.	65	45	12	4	3	1	3
Jacksonville, Fla.	U	U	U	U	U	U	U
Miami, Fla.	167	112	28	17	2	8	10
Norfolk, Va.	68	43	15	6	3	1	4
Richmond, Va.	62	35	15	5	4	3	6
Savannah, Ga.	67	50	11	5	-	1	5
St. Petersburg, Fla.	60	45	9	6	-	-	-
Tampa, Fla.	171	117	30	22	1	1	6
Washington, D.C.	100	57	26	10	5	2	1
Wilmington, Del.	11	6	5	-	-	-	-
E.S. CENTRAL	789	528	170	59	22	10	49
Birmingham, Ala.	155	107	34	8	2	4	9
Chattanooga, Tenn.	59	43	7	3	3	3	1
Knoxville, Tenn.	108	77	20	8	3	-	5
Lexington, Ky.	U	U	U	U	U	U	U
Memphis, Tenn.	138	88	23	21	6	-	7
Mobile, Ala.	77	53	19	3	2	-	2
Montgomery, Ala.	53	32	13	6	2	-	1
Nashville, Tenn.	199	128	54	10	4	3	24
W.S. CENTRAL	1,550	996	316	143	49	46	100
Austin, Tex.	89	52	23	11	2	1	3
Baton Rouge, La.	70	44	17	8	-	1	1
Corpus Christi, Tex.	48	30	13	2	-	3	7
Dallas, Tex.	230	137	56	21	8	8	18
El Paso, Tex.	72	48	10	11	3	-	1
Ft. Worth, Tex.	170	115	30	14	4	7	5
Houston, Tex.	369	221	79	37	17	15	24
Little Rock, Ark.	70	49	12	2	3	4	4
New Orleans, La.	U	U	U	U	U	U	U
San Antonio, Tex.	214	147	40	19	5	3	20
Shreveport, La.	46	33	6	3	3	1	6
Tulsa, Okla.	172	120	30	15	4	3	11
MOUNTAIN	944	615	211	67	24	21	66
Albuquerque, N.M.	130	82	33	11	3	1	10
Boise, Idaho	51	36	9	4	-	1	4
Colo. Springs, Colo.	64	46	12	1	2	3	3
Denver, Colo.	102	69	23	4	1	5	6
Las Vegas, Nev.	247	153	64	23	4	3	12
Ogden, Utah	33	28	4	-	1	-	3
Phoenix, Ariz.	154	87	35	15	7	5	12
Pueblo, Colo.	39	33	6	-	-	-	2
Salt Lake City, Utah	124	81	25	9	6	3	14
Tucson, Ariz.	U	U	U	U	U	U	U
PACIFIC	1,430	1,068	241	73	24	23	117
Berkeley, Calif.	16	10	5	-	-	1	1
Fresno, Calif.	64	50	9	2	3	-	4
Glendale, Calif.	1	1	-	-	-	-	-
Honolulu, Hawaii	58	42	12	3	1	-	4
Long Beach, Calif.	82	62	15	2	1	2	12
Los Angeles, Calif.	121	81	19	12	4	5	6
Pasadena, Calif.	20	19	1	-	-	-	8
Portland, Oreg.	131	97	21	7	5	1	7
Sacramento, Calif.	213	147	44	13	3	6	20
San Diego, Calif.	164	137	19	5	-	3	11
San Francisco, Calif.	U	U	U	U	U	U	U
San Jose, Calif.	231	174	35	15	4	3	25
Santa Cruz, Calif.	45	41	4	-	-	-	2
Seattle, Wash.	130	95	26	6	1	2	7
Spokane, Wash.	55	38	12	4	1	-	4
Tacoma, Wash.	99	74	19	4	1	-	6
TOTAL	10,800¶	7,369	2,106	846	258	212	687

U: Unavailable. -:No reported cases.

* Mortality data in this table are reported voluntarily from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¶ Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending December 29, 2001, with historical data



* No measles or rubella cases were reported for the current 4-week period yielding a ratio for week 52 of zero (0).

† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending December 29, 2001 (52nd Week)*

	Cum. 2001		Cum. 2001
Anthrax	16	Poliomyelitis, paralytic	-
Brucellosis†	95	Psittacosis†	27
Cholera	4	Q fever†	23
Cyclosporiasis†	127	Rabies, human	1
Diphtheria	2	Rocky Mountain spotted fever (RMSF)	614
Ehrlichiosis: human granulocytic (HGE)†	215	Rubella, congenital syndrome	2
human monocytic (HME)†	101	Streptococcal disease, invasive, group A	3,720
Encephalitis: California serogroup viral†	104	Streptococcal toxic-shock syndrome†	55
eastern equine†	8	Syphilis, congenital¶	240
St. Louis†	3	Tetanus	27
western equine†	-	Toxic-shock syndrome	128
Hansen disease (leprosy)†	90	Trichinosis	25
Hantavirus pulmonary syndrome†	6	Tularemia†	107
Hemolytic uremic syndrome, postdiarrheal†	166	Typhoid fever	322
HIV infection, pediatric†§	225	Yellow fever	-
Plague	2		

-: No reported cases.
*Incidence data for reporting year 2001 are provisional and cumulative (year-to-date).
† Not notifiable in all states.
§ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last updated December 25, 2001.
¶ Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	AIDS		Chlamydia§		Cryptosporidiosis		*Escherichia coli* O157:H7†			
							NETSS		PHLIS	
	Cum. 2001¶	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	42,008	38,864	710,690	697,757	3,496	3,128	3,130	4,528	2,237	3,620
NEW ENGLAND	1,565	2,008	23,253	23,431	130	143	224	380	228	382
Maine	48	40	1,334	1,474	19	20	27	32	27	29
N.H.	40	30	1,353	1,130	17	25	36	40	31	39
Vt.	25	38	633	526	34	28	14	37	10	37
Mass.	765	1,188	10,068	10,065	51	37	115	167	112	175
R.I.	103	99	2,875	2,632	9	4	17	20	11	18
Conn.	584	613	6,990	7,604	-	29	15	84	37	84
MID. ATLANTIC	11,301	8,429	83,067	68,426	300	393	252	443	181	348
Upstate N.Y.	1,584	703	15,409	5,316	112	139	160	303	136	82
N.Y. City	6,115	4,165	29,065	26,170	107	171	14	23	11	18
N.J.	1,761	1,891	13,020	10,814	26	19	78	117	34	119
Pa.	1,841	1,670	25,573	26,126	55	64	N	N	-	129
E.N. CENTRAL	3,031	3,705	117,412	120,473	1,489	983	793	1,103	505	755
Ohio	584	588	24,318	31,190	187	260	230	275	155	226
Ind.	378	383	14,805	13,735	81	72	85	131	43	88
Ill.	1,327	1,760	33,544	32,991	437	126	163	194	135	158
Mich.	549	761	30,148	26,237	180	97	101	141	82	104
Wis.	193	213	14,597	16,320	604	428	214	362	90	179
W.N. CENTRAL	892	936	35,861	40,126	521	422	566	683	457	624
Minn.	157	185	7,286	8,102	185	190	278	212	212	231
Iowa	90	93	4,611	5,987	81	77	79	180	62	148
Mo.	445	452	13,085	13,448	46	31	61	111	94	98
N. Dak.	3	3	874	908	15	18	18	23	34	21
S. Dak.	25	8	1,751	1,834	8	15	43	56	41	59
Nebr.	74	68	2,220	3,791	182	82	60	71	-	49
Kans.	98	127	6,034	6,056	4	9	27	30	14	18
S. ATLANTIC	12,594	11,041	132,655	132,950	350	524	252	387	149	294
Del.	248	220	2,793	2,856	6	9	4	3	7	1
Md.	1,860	1,457	12,275	14,528	40	14	28	35	1	2
D.C.	870	873	3,145	3,205	13	18	-	1	U	U
Va.	951	819	17,358	15,352	27	21	50	77	42	68
W. Va.	100	61	2,318	2,135	2	3	10	15	8	13
N.C.	947	673	19,907	22,175	31	28	58	93	43	75
S.C.	729	789	10,506	9,950	7	-	23	21	11	16
Ga.	1,750	1,238	28,739	29,359	132	191	33	44	15	40
Fla.	5,139	4,911	35,614	33,390	92	240	46	98	22	79
E.S. CENTRAL	1,793	1,960	49,467	51,156	52	51	137	151	112	119
Ky.	333	210	8,874	8,063	5	7	63	40	49	33
Tenn.	602	839	15,391	15,073	16	12	46	62	48	55
Ala.	438	482	14,155	15,323	18	16	18	10	6	9
Miss.	420	429	11,047	12,697	13	16	10	39	9	22
W.S. CENTRAL	4,196	3,851	102,586	102,286	121	175	115	227	91	285
Ark.	200	194	6,695	6,219	9	16	14	56	-	38
La.	861	662	16,871	17,922	7	14	4	15	26	54
Okla.	243	354	10,222	9,331	15	30	36	19	28	17
Tex.	2,892	2,641	68,798	68,814	90	115	61	137	37	176
MOUNTAIN	1,387	1,389	41,626	37,271	242	182	296	424	171	306
Mont.	15	16	1,855	1,469	37	10	20	31	-	-
Idaho	19	22	1,939	1,907	23	28	81	73	39	41
Wyo.	5	11	840	807	7	5	7	21	1	11
Colo.	288	326	10,526	9,161	44	72	89	156	54	110
N. Mex.	143	140	5,767	5,204	29	25	17	22	11	18
Ariz.	541	443	14,348	12,514	11	10	31	56	23	45
Utah	124	148	1,870	2,190	85	28	33	50	42	71
Nev.	252	283	4,481	4,019	6	4	18	15	1	10
PACIFIC	5,249	5,545	124,763	121,638	291	255	495	730	343	507
Wash.	533	498	13,361	13,066	7	U	135	237	62	206
Oreg.	259	207	7,457	7,107	54	20	84	134	61	115
Calif.	4,315	4,702	97,460	95,349	226	235	251	313	211	169
Alaska	18	23	2,645	2,569	1	-	4	32	1	6
Hawaii	124	115	3,840	3,547	3	-	21	14	8	11
Guam	12	13	-	492	-	-	N	N	U	U
P.R.	1,242	1,346	2,404	U	-	-	1	7	U	U
V.I.	35	34	53	-	-	-	-	-	U	U
Amer. Samoa	1	-	U	U	U	U	U	U	U	U
C.N.M.I.	-	-	129	U	-	U	-	U	U	U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

§ Chlamydia refers to genital infections caused by *C. trachomatis*.

¶ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last updated December 25, 2001.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	Gonorrhea		Hepatitis C; Non-A, Non-B		Legionellosis		Listeriosis	Lyme Disease	
	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	326,346	357,570	3,227	3,197	1,085	1,127	542	13,452	17,730
NEW ENGLAND	6,707	6,613	32	36	73	56	46	4,044	5,801
Maine	141	90	-	2	8	2	2	-	71
N.H.	180	110	-	-	12	4	4	117	84
Vt.	75	65	7	5	5	5	3	18	40
Mass.	3,167	2,775	25	22	21	18	26	895	1,158
R.I.	826	661	-	7	13	9	3	493	675
Conn.	2,318	2,912	-	-	14	18	8	2,521	3,773
MID. ATLANTIC	41,784	40,701	1,598	652	230	306	91	7,077	9,131
Upstate N.Y.	8,888	8,442	58	46	69	100	30	3,688	4,152
N.Y. City	12,404	11,672	-	-	39	47	19	10	177
N.J.	7,645	7,232	1,473	561	25	23	25	1,854	2,459
Pa.	12,847	13,355	67	45	97	136	17	1,525	2,343
E.N. CENTRAL	61,508	71,565	162	235	312	292	75	677	773
Ohio	13,607	19,303	9	12	149	121	17	113	61
Ind.	6,732	6,417	1	-	25	41	8	23	23
Ill.	18,735	20,671	15	21	19	33	16	22	35
Mich.	17,079	18,182	137	202	83	53	24	17	23
Wis.	5,355	6,992	-	-	36	44	10	502	631
W.N. CENTRAL	15,360	18,114	755	637	49	69	21	401	570
Minn.	2,372	3,160	13	15	9	16	3	333	465
Iowa	1,224	1,392	-	2	8	15	2	36	34
Mo.	8,062	8,883	722	605	23	26	10	26	47
N. Dak.	40	73	-	1	1	1	-	-	2
S. Dak.	278	277	-	-	3	2	-	-	-
Nebr.	713	1,534	8	5	4	5	1	4	5
Kans.	2,671	2,795	12	9	1	4	5	2	17
S. ATLANTIC	81,772	93,591	127	128	219	211	82	965	1,176
Del.	1,733	1,735	7	2	12	10	2	151	167
Md.	6,983	9,836	17	16	37	70	16	563	688
D.C.	2,816	2,706	-	3	8	7	-	17	11
Va.	10,428	10,175	2	3	28	37	15	119	149
W. Va.	721	643	9	23	N	N	5	13	35
N.C.	15,823	17,937	22	20	11	16	6	41	47
S.C.	6,943	8,383	6	3	14	7	5	7	25
Ga.	15,889	19,395	1	4	10	10	14	-	-
Fla.	20,436	22,781	63	54	99	54	19	54	54
E.S. CENTRAL	31,955	36,659	182	466	57	45	21	64	50
Ky.	3,584	3,502	10	40	12	22	5	23	13
Tenn.	10,069	11,877	67	112	30	15	9	30	28
Ala.	11,032	12,063	5	10	13	5	7	10	6
Miss.	7,270	9,217	100	304	2	3	-	1	3
W.S. CENTRAL	50,083	54,056	179	755	13	27	29	82	93
Ark.	4,162	3,642	4	12	-	-	1	1	7
La.	11,600	13,266	90	456	2	7	-	2	8
Okla.	4,688	4,229	4	16	3	5	2	-	1
Tex.	29,633	32,919	81	271	8	15	26	79	77
MOUNTAIN	10,017	10,365	61	97	60	47	38	13	16
Mont.	101	60	1	5	-	2	-	-	-
Idaho	74	98	2	3	3	5	1	5	4
Wyo.	78	53	9	2	1	-	2	1	3
Colo.	3,071	3,112	14	18	19	15	10	1	-
N. Mex.	969	1,152	12	16	3	1	7	1	-
Ariz.	3,918	4,106	9	22	23	11	9	2	2
Utah	142	231	3	13	7	12	2	1	3
Nev.	1,664	1,553	11	18	4	1	7	2	4
PACIFIC	27,160	25,906	131	191	72	74	139	129	120
Wash.	2,940	2,418	23	44	10	19	11	9	9
Oreg.	1,144	1,038	13	27	N	N	9	14	13
Calif.	22,065	21,606	95	118	58	54	113	104	96
Alaska	434	361	-	-	-	-	-	2	2
Hawaii	577	483	-	2	4	1	6	N	N
Guam	-	57	-	3	-	-	-	-	-
P.R.	578	527	1	1	2	1	-	N	N
V.I.	6	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	-	U	U
C.N.M.I.	14	U	-	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	Malaria		Rabies, Animal		Salmonellosis†			
					NETSS		PHLIS	
	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	1,266	1,560	6,563	6,934	38,367	39,574	28,019	31,949
NEW ENGLAND	91	79	737	829	2,312	2,191	2,124	2,209
Maine	5	7	69	139	167	127	151	101
N.H.	2	1	21	23	164	148	155	149
Vt.	1	4	62	57	83	110	71	104
Mass.	38	32	273	277	1,314	1,236	1,116	1,250
R.I.	16	13	72	60	143	152	173	158
Conn.	29	22	240	273	441	418	458	447
MID. ATLANTIC	380	392	1,187	1,294	5,005	5,045	3,648	5,266
Upstate N.Y.	69	80	772	823	1,275	1,293	1,213	1,281
N.Y. City	201	228	35	18	1,099	1,197	1,357	1,281
N.J.	76	49	192	195	1,598	1,138	657	1,025
Pa.	34	35	188	258	1,033	1,417	421	1,679
E.N. CENTRAL	141	155	143	169	4,854	5,451	4,101	3,700
Ohio	27	23	52	52	1,359	1,602	1,165	1,456
Ind.	16	11	15	14	529	678	482	613
Ill.	35	68	24	22	1,317	1,502	1,169	303
Mich.	42	34	46	69	839	904	791	942
Wis.	21	19	6	12	810	765	494	386
W.N. CENTRAL	35	84	364	542	2,357	2,483	2,328	2,509
Minn.	6	42	46	98	706	614	665	679
Iowa	9	2	82	81	340	373	301	350
Mo.	13	21	40	50	639	713	940	859
N. Dak.	-	3	42	117	60	73	84	78
S. Dak.	-	1	56	96	147	100	118	103
Nebr.	2	8	4	3	153	231	-	139
Kans.	5	7	94	97	312	379	220	301
S. ATLANTIC	296	382	2,310	2,402	9,521	8,629	5,912	5,908
Del.	2	5	30	49	86	125	112	134
Md.	113	126	361	413	812	804	853	730
D.C.	13	17	-	-	81	64	U	U
Va.	49	55	485	574	1,320	1,020	1,041	931
W. Va.	1	4	140	114	142	181	140	152
N.C.	19	36	577	571	1,378	1,149	1,219	1,136
S.C.	8	2	114	163	899	781	723	575
Ga.	30	47	399	357	1,661	1,689	1,210	1,722
Fla.	61	90	204	161	3,142	2,816	614	528
E.S. CENTRAL	34	48	202	210	2,630	2,483	1,788	1,832
Ky.	12	18	28	21	383	393	230	269
Tenn.	12	13	106	107	651	709	788	819
Ala.	6	16	64	81	748	676	474	607
Miss.	4	1	4	1	848	705	296	137
W.S. CENTRAL	12	73	1,045	880	4,168	4,952	2,537	3,020
Ark.	3	3	20	32	903	729	92	578
La.	5	14	3	4	424	877	952	755
Okla.	3	10	60	58	482	405	375	302
Tex.	1	46	962	786	2,359	2,941	1,118	1,385
MOUNTAIN	63	60	232	294	2,212	2,786	1,801	2,494
Mont.	3	1	38	65	78	97	-	-
Idaho	4	5	28	10	146	132	95	118
Wyo.	-	-	20	78	57	76	52	60
Colo.	23	30	-	-	592	692	577	677
N. Mex.	3	-	14	21	280	239	235	208
Ariz.	17	11	116	101	659	798	627	770
Utah	4	6	15	10	225	487	192	479
Nev.	9	7	1	9	175	265	23	182
PACIFIC	214	287	343	314	5,308	5,554	3,780	5,011
Wash.	15	43	-	-	579	659	491	677
Oreg.	14	40	3	7	248	297	309	360
Calif.	174	194	300	272	4,063	4,300	2,622	3,693
Alaska	1	-	40	35	51	61	28	36
Hawaii	10	10	-	-	367	237	330	245
Guam	-	2	-	-	-	28	U	U
P.R.	5	5	90	80	556	742	U	U
V.I.	-	-	-	-	-	-	U	U
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	16	U	U	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	Shigellosis† NETSS Cum. 2001	Shigellosis† NETSS Cum. 2000	Shigellosis† PHLIS Cum. 2001	Shigellosis† PHLIS Cum. 2000	Syphilis (Primary & Secondary) Cum. 2001	Syphilis (Primary & Secondary) Cum. 2000	Tuberculosis Cum. 2001	Tuberculosis Cum. 2000
UNITED STATES	18,653	22,922	7,747	12,709	5,790	5,978	12,294	15,976
NEW ENGLAND	273	409	276	384	68	85	420	489
Maine	6	11	3	11	1	1	3	24
N.H.	7	7	4	8	1	2	17	22
Vt.	7	4	6	-	3	-	4	4
Mass.	199	283	185	262	43	62	246	285
R.I.	24	35	26	34	9	4	49	49
Conn.	30	69	52	69	11	16	101	105
MID. ATLANTIC	1,394	2,879	724	1,723	493	280	2,255	2,575
Upstate N.Y.	476	859	113	212	30	15	351	412
N.Y. City	356	939	362	628	271	117	1,124	1,332
N.J.	366	508	184	439	143	71	496	565
Pa.	196	573	65	444	49	77	284	266
E.N. CENTRAL	4,329	4,215	1,837	1,329	1,020	1,207	1,368	1,607
Ohio	2,974	437	1,182	332	76	69	273	340
Ind.	225	1,591	50	156	159	351	111	145
Ill.	542	1,188	362	179	360	412	636	743
Mich.	302	667	216	606	403	330	268	287
Wis.	286	332	27	56	22	45	80	92
W.N. CENTRAL	1,983	2,627	1,267	2,060	85	64	451	551
Minn.	467	901	440	925	28	16	232	178
Iowa	370	569	290	350	4	11	34	40
Mo.	307	671	218	463	22	29	136	211
N. Dak.	22	61	35	52	-	-	4	5
S. Dak.	643	8	246	6	1	-	13	16
Nebr.	98	162	-	117	5	2	32	24
Kans.	76	255	38	147	25	6	-	77
S. ATLANTIC	2,996	3,196	841	1,169	1,910	2,009	2,584	3,266
Del.	17	25	14	23	12	9	15	14
Md.	164	202	91	115	253	307	232	282
D.C.	53	80	U	U	43	37	51	38
Va.	640	460	268	350	105	126	256	292
W. Va.	8	26	10	17	5	3	28	33
N.C.	356	400	170	270	431	483	398	447
S.C.	251	144	123	94	222	229	207	286
Ga.	451	339	130	193	366	402	445	703
Fla.	1,056	1,520	35	107	473	413	952	1,171
E.S. CENTRAL	1,663	1,213	608	586	660	877	810	1,013
Ky.	813	530	327	121	48	85	115	147
Tenn.	113	354	120	379	329	532	294	383
Ala.	211	100	130	79	148	123	265	310
Miss.	526	229	31	7	135	137	136	173
W.S. CENTRAL	2,502	3,525	1,146	1,165	752	825	803	2,190
Ark.	543	235	155	63	45	104	153	199
La.	149	300	166	200	169	209	-	331
Okla.	109	131	36	44	67	116	138	154
Tex.	1,701	2,859	789	858	471	396	512	1,506
MOUNTAIN	997	1,295	708	868	230	225	545	589
Mont.	9	8	-	-	-	-	14	21
Idaho	40	44	15	25	1	1	10	16
Wyo.	3	5	5	3	1	1	3	4
Colo.	246	269	258	221	22	11	120	97
N. Mex.	121	188	79	119	17	16	25	45
Ariz.	444	577	290	350	173	189	269	261
Utah	67	82	53	84	8	2	35	49
Nev.	67	122	8	66	8	5	69	96
PACIFIC	2,516	3,563	340	3,425	572	406	3,058	3,696
Wash.	218	501	167	414	54	66	258	258
Oreg.	96	164	111	110	13	12	108	119
Calif.	2,132	2,853	-	2,865	493	326	2,493	3,075
Alaska	7	7	6	3	-	-	51	108
Hawaii	63	38	56	33	12	2	148	136
Guam	-	46	U	U	-	3	-	53
P.R.	9	39	U	U	257	175	76	174
V.I.	-	-	U	U	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	8	U	U	U	13	U	32	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	*H. influenzae*, Invasive		Hepatitis (Viral), By Type				Measles (Rubeola)					
			A		B		Indigenous		Imported†		Total	
	Cum. 2001§	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	1,428	1,398	10,777	13,397	6,718	8,036	-	61	-	47	108	86
NEW ENGLAND	93	132	664	399	98	140	-	4	-	1	5	6
Maine	2	2	11	22	5	5	-	-	-	-	-	-
N.H.	7	14	18	19	16	19	-	-	-	-	-	3
Vt.	5	10	16	10	4	6	-	1	-	-	1	3
Mass.	41	46	311	139	11	15	-	2	-	1	3	-
R.I.	7	9	74	31	31	46	-	-	-	-	-	-
Conn.	31	51	234	178	31	49	-	1	-	-	1	-
MID. ATLANTIC	234	243	1,197	1,527	1,173	1,165	-	5	-	11	16	24
Upstate N.Y.	79	109	283	265	133	154	-	1	-	4	5	10
N.Y. City	51	65	308	528	457	556	-	3	-	1	4	13
N.J.	81	41	401	288	338	179	-	-	-	1	1	-
Pa.	23	28	205	446	245	276	-	1	-	5	6	1
E.N. CENTRAL	227	186	1,216	1,691	901	832	-	-	-	10	10	10
Ohio	74	55	261	267	93	107	-	-	-	3	3	3
Ind.	51	33	104	132	48	84	-	-	-	4	4	-
Ill.	63	62	458	696	152	170	-	-	-	3	3	3
Mich.	13	11	324	491	608	427	-	-	-	-	-	3
Wis.	26	25	69	105	-	44	-	-	-	-	-	1
W.N. CENTRAL	74	86	404	666	213	321	-	4	-	1	5	3
Minn.	47	51	42	185	31	58	-	2	-	1	3	1
Iowa	-	-	36	67	22	38	-	-	-	-	-	-
Mo.	16	23	105	258	108	149	-	2	-	-	2	-
N. Dak.	7	4	3	4	2	3	-	-	-	-	-	-
S. Dak.	-	1	3	3	1	2	-	-	-	-	-	-
Nebr.	2	3	35	38	28	44	-	-	-	-	-	-
Kans.	2	4	180	111	21	27	-	-	-	-	-	2
S. ATLANTIC	391	333	2,738	1,771	1,614	1,630	-	4	-	1	5	4
Del.	-	-	15	15	11	15	-	-	-	-	-	-
Md.	93	81	324	210	144	131	-	2	-	1	3	-
D.C.	-	-	73	40	13	35	-	-	-	-	-	-
Va.	30	41	143	164	186	174	-	1	-	-	1	2
W. Va.	16	15	28	56	25	30	-	-	-	-	-	-
N.C.	50	23	242	154	222	256	-	-	-	-	-	-
S.C.	9	7	78	97	32	23	-	-	-	-	-	-
Ga.	104	85	969	376	466	350	-	1	-	-	1	-
Fla.	89	81	866	659	515	616	-	-	-	-	-	2
E.S. CENTRAL	77	54	421	418	435	501	-	2	-	-	2	-
Ky.	2	12	137	63	51	81	-	2	-	-	2	-
Tenn.	44	26	173	156	242	239	-	-	-	-	-	-
Ala.	29	14	81	56	88	71	-	-	-	-	-	-
Miss.	2	2	30	143	54	110	-	-	-	-	-	-
W.S. CENTRAL	55	68	1,338	2,460	674	1,503	-	-	-	1	1	1
Ark.	2	2	68	144	102	109	-	-	-	-	-	1
La.	6	16	61	107	48	157	-	-	-	-	-	-
Okla.	45	46	120	272	107	178	-	-	-	-	-	-
Tex.	2	4	1,089	1,937	417	1,059	-	-	-	1	1	-
MOUNTAIN	165	135	746	977	488	580	-	2	-	-	2	12
Mont.	-	1	13	7	3	8	U	-	U	-	-	-
Idaho	2	4	57	45	11	10	-	1	-	-	1	-
Wyo.	-	1	7	4	3	3	-	-	-	-	-	-
Colo.	38	33	90	223	103	108	-	-	-	-	-	2
N. Mex.	28	26	37	70	131	144	-	-	-	-	-	-
Ariz.	74	53	411	467	161	215	-	1	-	-	1	-
Utah	12	11	69	71	28	37	-	-	-	-	-	3
Nev.	11	6	62	90	48	55	-	-	-	-	-	7
PACIFIC	112	161	2,053	3,488	1,122	1,364	-	40	-	22	62	26
Wash.	7	9	161	298	143	132	-	13	-	2	15	3
Oreg.	24	34	82	172	119	124	-	4	-	-	4	-
Calif.	51	48	1,793	2,992	831	1,083	-	21	-	15	36	19
Alaska	6	45	14	13	9	13	-	-	-	-	-	1
Hawaii	24	25	3	13	20	12	-	2	-	5	7	3
Guam	-	3	-	1	-	10	-	-	-	-	-	-
P.R.	1	4	132	255	188	313	-	-	-	-	-	3
V.I.	-	-	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	35	U	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.

* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

† For imported measles, cases include only those resulting from importation from other countries.

§ Of 290 cases among children aged <5 years, serotype was reported for 129, and of those, 22 were type b.

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 29, 2001, and December 30, 2000 (52nd Week)*

Reporting Area	Meningococcal Disease		Mumps			Pertussis			Rubella		
	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000
UNITED STATES	2,255	2,256	2	231	338	96	5,396	7,867	-	19	176
NEW ENGLAND	115	123	-	-	5	23	579	1,952	-	-	12
Maine	7	9	-	-	-	-	21	46	-	-	-
N.H.	14	12	-	-	-	-	39	159	-	-	2
Vt.	7	4	-	-	-	23	107	254	-	-	-
Mass.	56	70	-	-	1	-	389	1,411	-	-	8
R.I.	6	9	-	-	1	-	6	28	-	-	1
Conn.	25	19	-	-	3	-	17	54	-	-	1
MID. ATLANTIC	255	262	-	24	31	1	307	819	-	5	11
Upstate N.Y.	64	79	-	4	12	1	150	385	-	1	1
N.Y. City	42	46	-	12	8	-	49	90	-	3	9
N.J.	93	54	-	4	4	-	22	56	-	1	1
Pa.	56	83	-	4	7	-	86	288	-	-	-
E.N. CENTRAL	326	403	-	20	27	1	739	942	-	2	1
Ohio	92	94	-	1	9	-	326	389	-	-	-
Ind.	43	59	-	3	2	-	96	153	-	-	-
Ill.	72	91	-	11	6	-	80	133	-	2	1
Mich.	71	115	-	5	7	1	139	127	-	-	-
Wis.	48	44	-	-	3	-	98	140	-	-	-
W.N. CENTRAL	165	157	-	17	26	5	443	829	-	3	2
Minn.	27	23	-	5	7	-	207	575	-	-	1
Iowa	31	37	-	1	8	2	81	67	-	1	-
Mo.	56	67	-	4	5	3	108	97	-	1	-
N. Dak.	6	3	-	-	1	-	5	9	-	-	-
S. Dak.	5	6	-	-	-	-	5	11	-	-	-
Nebr.	25	9	-	1	2	-	7	28	-	-	1
Kans.	15	12	-	6	3	-	30	42	-	1	-
S. ATLANTIC	380	337	-	42	50	2	356	593	-	5	119
Del.	5	1	-	-	-	-	-	9	-	-	1
Md.	42	28	-	7	9	-	45	133	-	-	-
D.C.	-	-	-	-	-	-	1	3	-	-	-
Va.	44	42	-	8	11	1	142	134	-	-	-
W. Va.	14	15	-	-	1	-	4	3	-	-	-
N.C.	63	39	-	5	9	-	74	129	-	-	89
S.C.	35	26	-	7	11	-	34	63	-	2	27
Ga.	52	53	-	7	2	-	27	52	-	1	-
Fla.	125	133	-	8	7	1	29	67	-	2	2
E.S. CENTRAL	134	137	-	9	7	3	188	132	-	-	6
Ky.	23	26	-	3	1	2	84	63	-	-	1
Tenn.	60	59	-	1	2	1	63	45	-	-	1
Ala.	35	36	-	-	4	-	37	20	-	-	4
Miss.	16	16	-	5	-	-	4	4	-	-	-
W.S. CENTRAL	340	245	-	14	38	7	543	452	-	2	10
Ark.	21	19	-	1	3	1	47	44	-	-	3
La.	66	46	-	2	5	-	3	21	-	-	1
Okla.	32	34	-	-	3	-	33	60	-	-	-
Tex.	221	146	-	11	27	6	460	327	-	2	6
MOUNTAIN	99	106	-	15	24	52	1,468	887	-	-	2
Mont.	4	6	U	1	1	U	54	35	U	-	-
Idaho	8	7	-	2	1	1	171	64	-	-	-
Wyo.	5	2	-	2	1	-	1	4	-	-	-
Colo.	36	35	-	3	1	8	344	488	-	-	1
N. Mex.	11	11	-	2	1	1	145	91	-	-	-
Ariz.	19	33	-	1	6	42	637	143	-	-	1
Utah	8	7	-	1	7	-	76	47	-	-	-
Nev.	8	5	-	3	6	-	40	15	-	-	-
PACIFIC	441	486	2	90	130	2	773	1,261	-	2	13
Wash.	66	71	-	2	10	1	171	458	-	-	7
Oreg.	46	70	N	N	N	1	53	110	-	-	-
Calif.	313	328	-	46	89	-	495	631	-	1	6
Alaska	3	9	-	1	8	-	11	21	-	-	-
Hawaii	13	8	2	41	23	-	43	41	-	1	-
Guam	-	-	-	-	16	-	-	4	-	-	1
P.R.	5	10	-	-	2	-	2	12	-	-	-
V.I.	-	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	U	-	U	U	-	U	U	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

TABLE IV. Deaths in 122 U.S. cities,* week ending December 29, 2001 (52nd Week)

Reporting Area	All Causes, By Age (Years)						P&I† Total
	All Ages	≥65	45-64	25-44	1-24	<1	
NEW ENGLAND	276	211	39	20	3	3	37
Boston, Mass.	U	U	U	U	U	U	U
Bridgeport, Conn.	U	U	U	U	U	U	U
Cambridge, Mass.	16	14	1	1	-	-	2
Fall River, Mass.	26	21	4	1	-	-	5
Hartford, Conn.	U	U	U	U	U	U	U
Lowell, Mass.	21	16	2	3	-	-	2
Lynn, Mass.	10	6	1	3	-	-	-
New Bedford, Mass.	29	27	1	1	-	-	-
New Haven, Conn.	31	22	6	2	1	-	3
Providence, R.I.	U	U	U	U	U	U	U
Somerville, Mass.	6	4	2	-	-	-	1
Springfield, Mass.	39	27	6	4	1	1	9
Waterbury, Conn.	43	34	7	-	1	1	6
Worcester, Mass.	55	40	9	5	-	1	9
MID. ATLANTIC	1,552	1,117	304	87	24	20	95
Albany, N.Y.	48	31	13	2	1	1	5
Allentown, Pa.	23	22	1	-	-	-	3
Buffalo, N.Y.	60	43	14	-	3	-	6
Camden, N.J.	22	12	7	2	-	1	1
Elizabeth, N.J.	21	16	5	-	-	-	-
Erie, Pa.§	25	22	3	-	-	-	4
Jersey City, N.J.	33	23	10	-	-	-	-
New York City, N.Y.	982	697	189	67	15	14	51
Newark, N.J.	U	U	U	U	U	U	U
Paterson, N.J.	31	15	11	4	1	-	-
Philadelphia, Pa.	U	U	U	U	U	U	U
Pittsburgh, Pa.§	29	21	8	-	-	-	2
Reading, Pa.	22	18	2	1	-	1	2
Rochester, N.Y.	124	92	21	6	4	1	8
Schenectady, N.Y.	34	28	5	1	-	-	3
Scranton, Pa.§	35	28	6	1	-	-	2
Syracuse, N.Y.	39	34	2	1	-	2	5
Trenton, N.J.	8	4	4	-	-	-	1
Utica, N.Y.	16	11	3	2	-	-	2
Yonkers, N.Y.	U	U	U	U	U	U	U
E.N. CENTRAL	1,027	683	219	63	32	30	58
Akron, Ohio	29	24	1	1	1	2	1
Canton, Ohio	33	22	7	3	1	-	4
Chicago, Ill.	U	U	U	U	U	U	U
Cincinnati, Ohio	58	36	17	-	3	2	1
Cleveland, Ohio	80	52	21	5	2	-	3
Columbus, Ohio	161	111	34	8	4	4	6
Dayton, Ohio	77	57	14	2	1	3	4
Detroit, Mich.	77	46	23	8	-	-	8
Evansville, Ind.	29	21	5	3	-	-	1
Fort Wayne, Ind.	46	33	7	2	3	1	2
Gary, Ind.	21	7	7	3	3	1	-
Grand Rapids, Mich.	32	18	8	1	1	4	2
Indianapolis, Ind.	122	79	23	11	3	6	11
Lansing, Mich.	U	U	U	U	U	U	U
Milwaukee, Wis.	83	50	20	6	5	2	4
Peoria, Ill.	U	U	U	U	U	U	U
Rockford, Ill.	45	30	8	6	-	1	2
South Bend, Ind.	28	18	8	2	-	-	2
Toledo, Ohio	63	42	11	2	5	3	5
Youngstown, Ohio	43	37	5	-	-	1	2
W.N. CENTRAL	572	383	118	42	21	8	42
Des Moines, Iowa	U	U	U	U	U	U	U
Duluth, Minn.	27	15	9	3	-	-	2
Kansas City, Kans.	43	23	9	4	6	1	3
Kansas City, Mo.	106	72	25	5	1	3	8
Lincoln, Nebr.	25	21	3	1	-	-	1
Minneapolis, Minn.	125	97	19	4	4	1	10
Omaha, Nebr.	49	35	11	3	-	-	2
St. Louis, Mo.	53	33	13	4	2	1	9
St. Paul, Minn.	63	43	13	4	2	1	4
Wichita, Kans.	81	44	16	14	6	1	3
S. ATLANTIC	990	635	206	102	26	21	69
Atlanta, Ga.	125	70	30	20	3	2	3
Baltimore, Md.	164	92	44	24	2	2	24
Charlotte, N.C.	79	47	19	10	1	2	14
Jacksonville, Fla.	118	75	27	8	5	3	3
Miami, Fla.	111	76	22	10	2	1	3
Norfolk, Va.	17	8	5	2	1	1	3
Richmond, Va.	39	31	5	1	1	1	2
Savannah, Ga.	71	52	8	7	2	2	5
St. Petersburg, Fla.	46	36	7	2	1	-	4
Tampa, Fla.	120	88	18	8	4	2	7
Washington, D.C.	100	60	21	10	4	5	1
Wilmington, Del.	U	U	U	U	U	U	U
E.S. CENTRAL	532	377	90	44	14	6	35
Birmingham, Ala.	100	65	23	5	4	2	9
Chattanooga, Tenn.	42	35	6	-	1	-	2
Knoxville, Tenn.	72	51	11	7	3	-	3
Lexington, Ky.	U	U	U	U	U	U	U
Memphis, Tenn.	162	118	26	13	2	3	17
Mobile, Ala.	44	34	5	4	1	-	1
Montgomery, Ala.	U	U	U	U	U	U	U
Nashville, Tenn.	112	74	19	15	3	1	3
W.S. CENTRAL	848	543	171	77	39	18	47
Austin, Tex.	67	41	16	7	3	-	3
Baton Rouge, La.	26	19	5	1	1	-	-
Corpus Christi, Tex.	56	38	12	5	1	-	7
Dallas, Tex.	115	60	36	8	10	1	9
El Paso, Tex.	27	20	4	-	1	2	-
Ft. Worth, Tex.	67	46	13	2	5	1	3
Houston, Tex.	284	167	54	38	15	10	11
Little Rock, Ark.	42	21	14	4	-	3	1
New Orleans, La.	U	U	U	U	U	U	U
San Antonio, Tex.	U	U	U	U	U	U	U
Shreveport, La.	56	46	6	3	1	-	9
Tulsa, Okla.	108	85	11	9	2	1	4
MOUNTAIN	668	472	132	45	10	8	60
Albuquerque, N.M.	79	60	12	5	1	1	12
Boise, Idaho	29	19	9	1	-	-	2
Colo. Springs, Colo.	38	26	8	4	-	-	-
Denver, Colo.	97	61	19	12	2	3	9
Las Vegas, Nev.	194	133	42	11	5	2	10
Ogden, Utah	29	24	5	-	-	-	4
Phoenix, Ariz.	U	U	U	U	U	U	U
Pueblo, Colo.	33	24	6	3	-	-	4
Salt Lake City, Utah	77	57	14	4	1	1	11
Tucson, Ariz.	92	68	17	5	1	1	8
PACIFIC	1,046	766	184	54	23	18	84
Berkeley, Calif.	18	12	3	2	-	-	3
Fresno, Calif.	59	46	9	2	2	-	7
Glendale, Calif.	5	4	1	-	-	-	-
Honolulu, Hawaii	66	52	5	7	1	1	6
Long Beach, Calif.	54	36	11	2	4	1	5
Los Angeles, Calif.	83	64	15	3	1	-	3
Pasadena, Calif.	17	10	3	-	1	3	1
Portland, Oreg.	167	131	25	4	1	6	12
Sacramento, Calif.	146	98	32	10	4	2	19
San Diego, Calif.	120	91	20	4	3	2	8
San Francisco, Calif.	U	U	U	U	U	U	U
San Jose, Calif.	127	93	24	5	3	2	8
Santa Cruz, Calif.	23	18	5	-	-	-	2
Seattle, Wash.	81	53	15	10	2	1	7
Spokane, Wash.	U	U	U	U	U	U	U
Tacoma, Wash.	80	58	16	5	1	-	3
TOTAL	7,511¶	5,187	1,463	534	192	132	527

U: Unavailable. -:No reported cases.

* Mortality data in this table are reported voluntarily from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¶ Total includes unknown ages.

Contributors to the Production of the *MMWR* (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.
Wayne S. Brathwaite

State Support Team
Robert Fagan
Jose Aponte
Gerald Jones
David Nitschke
Scott Noldy
Jim Vaughan
Carol A. Worsham

CDC Operations Team
Carol M. Knowles
Deborah A. Adams
Willie J. Anderson
Lateka M. Dammond
Patsy A. Hall
Mechele A. Hester
Felicia J. Connor
Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D.
Michele D. Renshaw Erica R. Shaver

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at *http://www.cdc.gov/mmwr* or from CDC's file transfer protocol server at *ftp://ftp.cdc.gov/pub/Publications/mmwr*. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

☆U.S. Government Printing Office: 2002-733-100/49034 Region IV